Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2014

View Archived Issues

Korean patent details novel mutant haptoglobins

Screening of circulating patient-derived breast cancer cells for tailored treatment

uniQure acquires InoCard

Janssen describes different series of FLAP inhibitors for inflammatory diseases

Novel glucocorticoid receptor agonists show selectivity for transrepression over transactivation

G2B Pharma receives financing and right to in-license nasal delivery technologies

Galenica lays foundation for two independent companies

The Michael J. Fox Foundation for Parkinson's Research updates on its Partnering Program

Carfilzomib fails to meet primary endpoint in phase III multiple myeloma trial

U.S. DTRA supports preclinical development of Evolva's GC-072 for acute melioidosis

Novel nontreponemal EIA assay for the diagnosis of syphilis

Actelion Pharmaceuticals discloses new P2X7 antagonists

University of Toledo patents novel anticancer agents

Neuraceq launched in U.S.

New metalloenzyme inhibitors designed by Viamet Pharmaceuticals

Novartis disclose novel p53-Mdm2 interaction inhibitors

Skyepharma acquires rights to inhaled therapy platform from Pulmagen

Ligand Pharmaceuticals signs Captisol license agreement with Avion Pharmaceuticals

FDA grants fast track designation to SPN-810

FDA grants fast track designation to AG-221 for acute myelogenous leukemia

Miltenyi Biotec acquires Lentigen's lentiviral vector business

Ablynx awarded grant supporting nanobody development for ocular applications

BioCryst receives additional NIAID funding to advance development of BCX-4430

FDA accepts Pfizer's rLP-2086 BLA for review and grants priority review status

FDA approves Avastin in combination with chemotherapy for advanced cervical cancer

Questcor Pharmaceuticals acquired by Mallinckrodt

FDA approves Plegridy for relapsing multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...